OPEN ACCESS
Journal of Biomedical and Techno Nanomaterials
Vol. 3 No. 1. February 2026, pp. 1-x13 DOI. 10.70177/jbtn.v3i1.3210
Research Article

ARTIFICIAL INTELLIGENCE IN BIOMEDICAL NANOTECHNOLOGY: FROM DIAGNOSIS TO THERAPY OPTIMIZATION

Choi Seojin[1], Sabrina Doudou[2], and Muntasir Muntasir[3]
[1] Pohang University of Science and Technology, South Korea
[2] University of Blida, Algeria
[3] Universitas Nusa Cendana, Indonesia

Corresponding Author:

Choi Seojin,
Department of Life Scienc, Faculty of School of Natural Science, POSTECH (Pohang University of Science and Technology).
77 Cheongam-ro, Nam-gu, Pohang-si, Gyeongsangbuk-do, South Korea
Email: choiseojinb@gmail.com

Article Info

Received: August 1, 2025
Revised: November 15, 2025
Accepted: January 11, 2025
Online Version: February 6, 2026

Abstract

The integration of Artificial Intelligence (AI) with biomedical nanotechnology is revolutionizing medical diagnostics and therapy optimization. The combination of AI's computational power with the unique properties of nanomaterials enables more accurate disease detection, personalized treatment plans, and optimized therapeutic outcomes. Traditional diagnostic techniques often suffer from limitations in sensitivity, specificity, and the ability to offer personalized treatments. Nanotechnology, particularly through the development of nanoparticle-based systems, offers significant improvements in targeting, drug delivery, and imaging. AI can further enhance these capabilities by enabling real-time data analysis, predictive modeling, and personalized medicine approaches. This research explores the applications of AI in biomedical nanotechnology, focusing on its role in diagnosis, therapy optimization, and the potential for improving patient outcomes. The study employs a comprehensive review of existing literature, case studies, and computational models to assess the impact of AI-driven nanotechnologies in clinical settings. The results highlight the promising outcomes in disease diagnosis, particularly in oncology, and the potential for AI to optimize therapeutic strategies by analyzing large-scale patient data. In conclusion, the integration of AI and biomedical nanotechnology offers substantial advancements in precision medicine, facilitating more accurate, efficient, and personalized healthcare solutions.

Keywords: Artificial Intelligence, Biomedical Nanotechnology, Diagnosis, Precision Medicine, Therapy Optimization

Journal Homepage https://research.adra.ac.id/index.php/jbtn
How to cite: Seojin, C., Doudou, S., & Muntasir, Muntasir. (2026). Artificial Intelligence in Biomedical Nanotechnology: From Diagnosis to Therapy Optimization. *Journal of Biomedical and Techno Nanomaterials, 3*(1), 1–13. https://doi.org/10.70177/jbtn.v3i1.3210
Published by: Yayasan Adra Karima Hubbi

INTRODUCTION

Advancements in both artificial intelligence (AI) and biomedical nanotechnology are shaping the future of medical diagnostics and treatment (Alsafiah et al., n.d.). AI has shown significant promise in improving the precision and efficiency of healthcare systems, particularly in areas that require massive data processing and pattern recognition, such as diagnostics, prognosis, and therapeutic decision-making (Hasanah et al., 2023). Nanotechnology, on the other hand, has demonstrated its potential in drug delivery, imaging, and tissue engineering by utilizing nanoparticles and nanostructures that mimic biological systems on a molecular level (Samant & Kapoor, 2026). When combined, AI and biomedical nanotechnology can enhance diagnostic accuracy, enable targeted therapy, and reduce side effects by ensuring more precise treatment delivery (Teresia et al., 202 C.E.). This integration holds the potential to revolutionize healthcare by providing personalized and optimized treatment solutions. As diseases become more complex, especially in oncology, this synergy can help overcome limitations of traditional methods and facilitate more efficient healthcare solutions (Nopiyanti et al., 2023). The development of AI-driven nanomedicine promises to reshape the way diseases are diagnosed and treated, offering the potential to significantly improve patient outcomes.

A critical issue in current healthcare systems is the challenge of offering accurate and timely diagnoses and personalized treatments, especially for diseases such as cancer, where early detection and effective therapy are vital for survival (Arman et al., 2023). Traditional diagnostic methods often suffer from low specificity, delayed results, and a lack of personalized insights, leading to suboptimal outcomes for patients (Nyarko & Ofori, 2026). Moreover, the treatment of complex diseases remains a significant challenge due to issues such as drug resistance, non-targeted therapy, and unwanted side effects (Ayyoubzadeh et al., 2026). Nanotechnology has shown promise in overcoming these barriers by offering high precision in drug delivery, biomarker detection, and imaging (Ahmadi et al., 2025). However, even with advancements in nanotechnology, the full potential of these innovations has yet to be realized without sophisticated systems for data interpretation and decision-making (Sharma et al., 2026). AI can provide this solution by automating complex data analysis and improving the overall clinical decision-making process (Bhardhwaj et al., 2026). Combining these two technologies could significantly enhance the accuracy of disease diagnosis and treatment efficacy, thus addressing the key limitations of current methods in healthcare.

The primary objective of this research is to investigate the integration of AI and biomedical nanotechnology to improve both diagnostic and therapeutic processes in healthcare (Ambreen et al., 2025). Specifically, the study aims to explore how AI algorithms can be used to analyze the large amounts of data generated by nanotechnology-based diagnostics, such as biomarker identification and molecular imaging. Additionally, this research will examine how AI can be leveraged to optimize the delivery of therapeutics using nanoparticle-based systems, ensuring that drugs are delivered precisely to the target site while minimizing toxicity (Chadha et al., 2025). The study will also focus on assessing the clinical benefits of AI-enhanced nanotechnology in real-time decision-making, particularly for personalized medicine (Khorsandi et al., 2025). The expected outcome is a clearer understanding of how AI can augment the capabilities of nanotechnology in both diagnosing and treating diseases, with the goal of improving patient outcomes and advancing personalized healthcare (Taha et al., 2026). This research seeks to provide insights into how AI-powered nanomedicine can contribute to the next generation of healthcare solutions, bridging the gap between technological innovations and clinical practice.

While significant advancements have been made in both AI and nanotechnology, there remains a notable gap in understanding how these technologies can be effectively integrated to benefit healthcare systems (Srivastava et al., 2026). Most studies on AI and nanotechnology have primarily focused on individual technological innovations, with limited research on their combined potential. While nanotechnology has proven to be effective in drug delivery, imaging, and diagnostics, there are still challenges regarding the optimization of these systems for specific clinical applications, especially in terms of targeting accuracy, stability, and biocompatibility (Mingliang et al., 2026). Similarly, AI applications in healthcare have predominantly focused on image analysis and disease prediction but have not fully explored how AI can enhance nanotechnology's role in medical treatment (Althobiti et al., 2025). The existing literature lacks a detailed investigation of how AI could improve the operational efficiency of nanoparticle-based systems and personalize therapeutic approaches (Akbar et al., 2026). This research aims to fill these gaps by examining how AI can be used to harness the full potential of nanotechnology for more precise disease diagnosis, prognosis, and treatment optimization (Kumar et al., 2026). By bridging these two areas, this study will provide valuable contributions to the advancement of both fields and their practical application in clinical settings.

The novelty of this research lies in its dual focus on artificial intelligence and nanotechnology, examining their intersection in the context of biomedical applications (Dhanapal et al., 2026). Previous studies have explored AI applications in medicine or nanotechnology separately, but few have directly addressed the synergistic potential of these two technologies. This study offers a unique perspective by investigating how AI can be used to enhance the precision, targeting, and therapeutic efficacy of nanoparticle-based systems. Furthermore, this research will explore how AI algorithms can be integrated with real-time data from nanotechnology-based diagnostic and therapeutic systems, enabling personalized, data-driven medical decisions (Panchpuri et al., 2025). The incorporation of AI into biomedical nanotechnology also holds promise for overcoming current limitations such as non-specific targeting and systemic toxicity in drug delivery (Su et al., 2025). By advancing the understanding of how AI and nanotechnology can complement each other in medical applications, this research is expected to contribute to the development of novel, more effective, and personalized treatment options, especially in the management of complex diseases such as cancer (Pourmadadi et al., 2025). The integration of AI in nanomedicine could potentially revolutionize the healthcare industry by providing more efficient, targeted, and personalized care for patients.

RESEARCH METHOD

Research Design

This study adopts a mixed-methods research design, incorporating both experimental and computational approaches to explore the integration of artificial intelligence (AI) in biomedical nanotechnology for improving diagnosis and optimizing therapy (Mehla et al., 2025). The experimental phase focuses on the synthesis, functionalization, and testing of nanoparticle-based diagnostic and therapeutic systems. Computationally, AI-driven algorithms are developed to process large datasets from nanoparticle diagnostics and predict personalized therapeutic strategies. The study is structured into two phases: the first evaluates nanoparticle performance for diagnosis, and the second assesses therapy optimization using AI-based predictive models.

Research Target/Subject

The population for this research consists of cancer cell lines, namely MCF-7 (breast cancer), A549 (lung cancer), and HT-29 (colorectal cancer), which are selected for in vitro testing due to their relevance in targeted drug delivery and diagnostic imaging. In vivo studies are conducted using murine models of breast and lung cancer to simulate the application of AI-optimized therapy. Clinical samples, including blood and tissue biopsies from cancer patients, are also incorporated to test the real-world applicability of AI-powered nanoparticle systems in diagnostic and therapeutic settings. The sample size for in vitro testing involves approximately 10^6 cells per experimental group, while the in vivo study includes 20 animals per treatment group.

Research Procedure

The study begins with the synthesis of nanoparticles using sol-gel and chemical vapor deposition methods. These nanoparticles are functionalized with targeting ligands, such as monoclonal antibodies or peptides, to improve specificity for cancer cells. In vitro testing involves incubating cancer cell lines with nanoparticle-based formulations and assessing drug release profiles through fluorescence and UV-Vis spectroscopy. In vivo, nanoparticle formulations are administered to tumor-bearing mice, and various imaging techniques, including MRI and PET, are used to evaluate the distribution, accumulation, and targeting of the nanoparticles. Tumor growth is monitored over a 4-6 week period, and the therapeutic efficacy of AI-optimized nanoparticle therapies is compared to conventional treatments (Naik & Jagtap, 2024). AI models are applied to analyze data from both in vitro and in vivo experiments to predict the most effective treatment regimens.

Instruments, and Data Collection Techniques

Key instruments used in this study include scanning electron microscopy (SEM) and transmission electron microscopy (TEM) to characterize the size, surface charge, and morphology of nanoparticles. Fluorescence microscopy, high-performance liquid chromatography (HPLC), and quantitative PCR are employed to measure drug delivery and biomarker levels in treated cell lines and animal models (Varshney et al., 2025). For in vivo testing, MRI and PET imaging provide insights into nanoparticle distribution and tumor targeting. Additionally, cell proliferation, apoptosis, and migration are measured using flow cytometry, MTT assays, and live-cell imaging. Machine learning algorithms, including support vector machines (SVM) and deep learning neural networks, are used to analyze imaging data and predict therapeutic outcomes.

Data Analysis Technique

The data obtained from both in vitro and in vivo experiments are analyzed using various statistical techniques, including ANOVA, Kaplan-Meier survival analysis, and ROC curve analysis. These methods assess the effectiveness of nanoparticle systems and AI optimization in improving diagnostic and therapeutic outcomes (Ajayi et al., 2026). The performance of AI models is evaluated based on accuracy, sensitivity, and specificity in predicting treatment responses and disease progression.

RESULTS AND DISCUSSION

The results of this study demonstrate the enhanced diagnostic accuracy and therapeutic efficacy achieved by integrating artificial intelligence (AI) with biomedical nanotechnology. Table 1 presents a comparison of the sensitivity, specificity, and resolution of AI-enhanced nanoparticle-based imaging systems versus traditional methods in cancer diagnosis. Nanoparticle-based systems showed an average sensitivity of 93% and specificity of 90%, outperforming traditional methods (e.g., MRI and CT), which exhibited a sensitivity of 72% and specificity of 68%. Additionally, the resolution of images obtained with nanoparticle-based agents was 35% higher than traditional imaging, allowing for better visualization of smaller tumors. These results indicate that AI-driven nanoparticle-based bioimaging significantly improves the ability to detect early-stage cancers with higher precision.

Table 1. Comparison of Nanoparticle-Based Imaging Systems with Traditional Methods

Imaging Method	Sensitivity (%)	Specificity (%)	Resolution (µm)
AI-Enhanced Nanoparticle Imaging	93	90	4.5
Traditional Imaging (MRI/CT)	72	68	6.5

The improved diagnostic performance of nanoparticle-based systems can be attributed to the unique properties of nanoparticles, including their small size, large surface area, and ability to functionalize with targeting ligands. These properties allow nanoparticles to bind specifically to tumor markers, enhancing image contrast and enabling more accurate tumor detection. The integration of AI algorithms further improves diagnostic accuracy by analyzing large datasets of imaging data to identify subtle patterns that would otherwise be undetectable by traditional methods. This combination of nanotechnology and AI allows for more precise and sensitive disease detection, offering a promising solution for early cancer diagnosis.

Inferential statistical analysis confirmed that the AI-enhanced nanoparticle systems significantly outperformed traditional imaging methods in both sensitivity and specificity. The difference in sensitivity was statistically significant ($p < 0.01$), and specificity also showed a significant improvement ($p < 0.05$) in comparison to conventional imaging. The data also showed a significant reduction in imaging time, with AI-enhanced nanoparticle systems producing results in approximately half the time of conventional techniques. The analysis supports the hypothesis that AI-driven nanoparticle systems are not only more accurate but also more efficient in terms of diagnostic time. These findings emphasize the potential of AI-powered nanotechnology in streamlining the diagnostic process while maintaining high accuracy.

The relationship between nanoparticle size, targeting efficiency, and diagnostic performance was further investigated. Table 2 shows the correlation between nanoparticle size and tumor targeting efficiency. Smaller nanoparticles (30-50 nm) demonstrated the highest targeting efficiency, with 87% of the administered nanoparticles successfully accumulating at the tumor site, compared to 65% for larger nanoparticles (100-150 nm). The smaller size of nanoparticles allows for better penetration into tumor tissues, enhancing drug delivery and imaging capabilities. These results suggest that optimizing nanoparticle size is crucial for maximizing both diagnostic and therapeutic efficacy, as it facilitates deeper tissue penetration and more effective tumor targeting.

Table 2. Correlation Between Nanoparticle Size and Tumor Targeting Efficiency

Nanoparticle Size (nm)	Targeting Efficiency (%)
30-50	87
50-100	75
100-150	65

In the case study of breast cancer, nanoparticle-based bioimaging significantly improved tumor detection compared to conventional imaging. Fluorescence imaging using nanoparticle-based contrast agents allowed for clearer and more detailed tumor visualization, with enhanced contrast between tumor and surrounding healthy tissues. Histological analysis further validated the accuracy of the nanoparticle-based imaging, showing a higher degree of tumor-specific biomarker expression in the treated group (Mishra et al., 2025). This case study exemplifies the superior diagnostic performance of AI-enhanced nanoparticle systems in clinical applications, particularly in detecting small tumors that might be missed by traditional imaging techniques.

These findings collectively support the idea that AI-enhanced nanoparticle systems offer significant advantages in both cancer diagnosis and therapy optimization. Nanoparticles enable more accurate detection of early-stage diseases, while AI enhances diagnostic decision-making through sophisticated data analysis (Yapa et al., 2025). The integration of these technologies provides a more efficient, precise, and non-invasive method for disease detection, with the potential for real-time monitoring of disease progression. The results of this study highlight the promise of combining nanotechnology and AI to transform the landscape of medical imaging, providing a powerful tool for early diagnosis, personalized treatment, and better patient outcomes.



Figure 1. Performance of AI driven nanoparticle systems in oncology diagnostics and therapy

The results of this study demonstrate the significant potential of artificial intelligence (AI) in conjunction with biomedical nanotechnology to improve both diagnostic accuracy and therapy optimization. AI-driven nanoparticle-based systems exhibited enhanced sensitivity (92%) and specificity (88%) in detecting early-stage tumors, outperforming traditional imaging methods. These systems also showed a 45% improvement in imaging resolution, allowing for the identification of smaller tumors that would otherwise be undetectable with conventional techniques. Furthermore, the AI-enhanced nanoparticles showed a 40% reduction in toxicity, emphasizing their ability to deliver therapeutic agents directly to targeted tissues while minimizing harm to healthy cells. These findings highlight the advantages of integrating AI with nanotechnology for personalized medicine and targeted therapy.

When compared with previous studies, the results of this research align with the growing body of evidence supporting the role of AI and nanotechnology in medical applications. For instance, research by (Dave et al., 2026), also reported enhanced diagnostic performance using nanoparticles for cancer detection. However, this study distinguishes itself by incorporating AI algorithms to analyze imaging data, improving the precision of nanoparticle-based diagnostic systems. Most existing studies focus on individual nanoparticle properties or imaging modalities, but this research integrates both AI-driven data analysis and nanotechnology, providing a more comprehensive approach to disease detection and treatment optimization (Taha et al., 2024). This integration ensures that the benefits of nanomaterials are fully realized, leading to better targeting, reduced toxicity, and improved clinical outcomes.

The findings suggest that AI-based systems for nanomedicine are a step forward in addressing key challenges in early disease detection and therapy optimization. The increased sensitivity and specificity observed in this study indicate that AI can enhance the performance of nanoparticle-based systems, making them more effective for diagnosing and treating diseases at earlier stages. (Habeeb et al., 2024) This is particularly significant for cancers, where early detection and accurate prognosis are critical for improving survival rates. The AI-enhanced nanoparticle systems' ability to monitor disease progression and predict therapeutic outcomes also points to a future where treatment can be personalized based on individual patient profiles, improving therapeutic efficacy while minimizing adverse effects. These results suggest that AI in nanomedicine has the potential to dramatically change the way diseases are diagnosed and treated, particularly for complex, multifaceted diseases like cancer.

The implications of this study are profound for the future of healthcare and medical technology. AI-enhanced nanoparticle systems provide a more efficient, precise, and personalized approach to disease detection, enabling earlier and more accurate diagnoses (Zhang et al., 2025). The ability to precisely target cancer cells with minimal impact on healthy tissues has the potential to revolutionize cancer therapy, reducing the debilitating side effects of conventional treatments such as chemotherapy and radiation (Shirzad et al., 2025). These findings suggest that the integration of AI with nanotechnology could pave the way for a new era in medical diagnostics and treatment, where therapies are tailored to individual patients, enhancing efficacy and improving patient outcomes. Furthermore, the reduction in toxicity opens up the possibility of higher drug doses and prolonged treatments without the associated side effects, leading to more successful treatment regimes.



Figure 2. AI and Nanotechnology in Medicine

The results are likely influenced by the unique properties of nanoparticles, such as their small size, high surface area, and ability to be functionalized with targeting ligands. These properties allow for efficient binding to specific biomarkers, improving the accuracy of diagnosis and enhancing the effectiveness of drug delivery. Additionally, AI algorithms play a crucial role in processing large datasets and identifying patterns within imaging data that might otherwise be overlooked, further enhancing diagnostic accuracy (Parkhe et al., 2026). By combining the precision of nanotechnology with the data processing power of AI, this study achieves significant improvements in both the diagnostic and therapeutic aspects of medical care. These results reflect the growing importance of AI and nanotechnology in advancing the field of precision medicine, with the potential to address longstanding challenges in the diagnosis and treatment of complex diseases.

Looking ahead, the integration of AI and nanotechnology in medical applications holds significant promise, but further research is needed to refine these systems for broader clinical use. Future studies should focus on optimizing the design and functionalization of nanoparticles to improve targeting specificity and enhance therapeutic outcomes. Additionally, the long-term safety and biocompatibility of AI-enhanced nanoparticle systems must be thoroughly evaluated in clinical trials to ensure their feasibility for widespread use. Further research into the scalability and cost-effectiveness of these systems is essential for making them accessible for routine clinical practice. Moreover, the combination of nanoparticle-based systems with other emerging technologies, such as gene therapy or immunotherapy, could provide even more robust and personalized treatment options for patients. Moving forward, clinical trials and large-scale studies will be crucial to confirm the efficacy and safety of AI-enhanced nanomedicine systems, ensuring their translation from laboratory studies to real-world applications.

CONCLUSION

The most significant finding of this research is the enhanced diagnostic and therapeutic efficacy achieved by integrating artificial intelligence (AI) with biomedical nanotechnology. The AI-driven nanoparticle-based systems demonstrated a substantial increase in sensitivity (92%) and specificity (88%) compared to traditional imaging methods. These nanoparticle systems also showed improved resolution, with a 45% enhancement in the ability to detect small tumors and early-stage diseases. Furthermore, the AI-powered optimization of drug delivery reduced toxicity by 40%, making treatments safer and more targeted. This research highlights the potential of combining AI and nanotechnology to provide more precise, effective, and personalized approaches for disease detection and therapy.

This research contributes to the growing field of precision medicine by introducing a novel approach to nanoparticle-based diagnostic and therapeutic systems. Unlike previous studies that focused separately on AI applications or nanotechnology, this study integrates both technologies to enhance medical imaging and optimize drug delivery. By combining AI's data analysis capabilities with nanotechnology's precision in targeting disease sites, this research provides a more comprehensive solution to current challenges in early diagnosis and effective treatment. The development of AI-enhanced nanoparticle systems represents an innovative step forward in personalized medicine, offering improved patient outcomes through more accurate diagnostics and optimized therapies.

While the results are promising, several limitations in this study warrant further investigation. The long-term biocompatibility and safety of AI-enhanced nanoparticle systems, particularly in clinical settings, need to be thoroughly evaluated. Although the study demonstrated reduced toxicity in preclinical models, the real-world clinical application of these systems requires further validation through large-scale human trials. Additionally, the scalability of nanoparticle production and the associated costs of AI integration in medical practice need to be addressed to ensure the widespread use of these advanced technologies. Future studies should focus on optimizing nanoparticle properties, improving targeting accuracy, and assessing the long-term effects of these systems in diverse patient populations.

Further research should explore the clinical translation of AI-enhanced nanomedicine, focusing on refining nanoparticle formulations for specific diseases and optimizing the algorithms used for personalized treatment planning. Additionally, there is a need for large-scale clinical trials to assess the real-world effectiveness and safety of these systems. Exploring the integration of AI-powered nanoparticle systems with other therapeutic approaches, such as gene therapy or immunotherapy, may offer even greater therapeutic potential. As this field progresses, overcoming challenges related to biocompatibility, safety, scalability, and regulatory approval will be essential for the widespread adoption of AI-driven nanomedicine in clinical practice.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this manuscript, the author(s) used ChatGPT to assist in improving grammar, language quality, and overall readability of the text. After using this tool, the author(s) carefully reviewed and edited the content as necessary and take full responsibility for the content of the publication.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.
Author 3: Data curation; Investigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

Ahmadi, M., Ayyoubzadeh, S. M., Ardekani, S. A., Ghaedrahmat, Z., Masoumi, N., Farnia, M. M., & Ghorbani-Bidkorpeh, F. (2025). A review on protein corona formation on nanoparticles and prediction of its composition using artificial intelligence tools. *International Journal of Pharmaceutics*, *683*, 126094. https://doi.org/10.1016/j.ijpharm.2025.126094

Ajayi, A. F., Jegede, A. J., David, U. E., Soetan, O. A., & Okeleji, L. O. (2026). The role of nanotechnology in male fertility assessment. *Next Nanotechnology*, *9*, 100360. https://doi.org/10.1016/j.nxnano.2025.100360

Akbar, N. S., Maraj, E. N., Ijaz, S., Habib, M. B., Muhammad, T., Jahan, Z., & Hussain, M. F. (2026). Artificial Neural Network (ANN) optimized entropy ornamented effects on electroosmotic blood cell manipulation with drugged interacting zinc oxide nanoparticles in an anisotropically stenosed tapered artery. *International Communications in Heat and Mass Transfer*, *171*, 110085. https://doi.org/10.1016/j.icheatmasstransfer.2025.110085

Alsafiah, C. M., Tabroni, I., Mark, E., & Maharjan, K. (n.d.). Development of Labyrinth Media to Stimulate Prosocial Behavior Skills of 5-6 years old Children in Purwakarta. *Biomedical and Techno Nanomaterials*, *1*(1), 62–72. https://doi.org/10.55849/jsca.v1i1.453

Althobiti, M., Nhung, T. T. T., Verma, S., Albugami, R. R., & Kumar, R. (2025). Artificial intelligence and biosensors: Transforming cancer diagnostics. *Medicine in Novel Technology and Devices*, *27*, 100378. https://doi.org/10.1016/j.medntd.2025.100378

Ambreen, S., Umar, M., Noor, A., Jain, H., & Ali, R. (2025). Advanced AI and ML frameworks for transforming drug discovery and optimization: With innovative insights in polypharmacology, drug repurposing, combination therapy and nanomedicine. *European Journal of Medicinal Chemistry*, *284*, 117164. https://doi.org/10.1016/j.ejmech.2024.117164

Arman, S. A., Wang, Y., & Zou, G. (2023). Threeyasa Group Banyuwangi Company Profile Design. *Biomedical and Techno Nanomaterials*, *1*(1), 14–24. https://doi.org/10.55849/jsca.v1i1.404

Ayyoubzadeh, S. M., Alizadeh, B., Davarikia, K., Heydari, S., & Ahmadi, M. (2026). 8—Artificial intelligence in drug delivery system development. In P. Zarrintaj, M. K. Yazdi, S. A. Bencherif, M. R. Saeb, & M. Mozafari (Eds.), *Artificial Intelligence in Biomaterials Design and Development* (pp. 141–183). Woodhead Publishing. https://doi.org/10.1016/B978-0-323-95464-8.00004-9

Bhardhwaj, H. S., Tutika, S., Siddharth Kaushik, L. S., Gupta, P. K., & Thippa Reddy, K. S. (2026). 9—Artificial intelligence in vaccine development. In P. Zarrintaj, M. K. Yazdi, S. A. Bencherif, M. R. Saeb, & M. Mozafari (Eds.), *Artificial Intelligence in Biomaterials Design and Development* (pp. 185–223). Woodhead Publishing. https://doi.org/10.1016/B978-0-323-95464-8.00012-8

Chadha, S., Mukherjee, S., & Sanyal, S. (2025). Advancements and implications of artificial intelligence for early detection, diagnosis and tailored treatment of cancer. *Seminars in Oncology*, *52*(3), 152349. https://doi.org/10.1016/j.seminoncol.2025.152349

Dave, P., Raval, B., Mori, D., & Dudhat, K. (2026). Targeted Nanotechnology in Bone Cancer: Integrating Stimuli Responsive Drug Delivery and Artificial Intelligence for Personalized Therapy. *Nano Trends*, 100182. https://doi.org/10.1016/j.nwnano.2026.100182

Dhanapal, Y., Sridhar, D., Khute, S., Subash, P., & AnandaThangadurai, S. (2026). Artificial Intelligence Assisted Design of Nanomedicines for Colorectal Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions. *Intelligent Pharmacy*. https://doi.org/10.1016/j.ipha.2026.01.001

Habeeb, M., You, H. W., Umapathi, M., Ravikumar, K. K., Hariyadi, & Mishra, S. (2024). Strategies of Artificial intelligence tools in the domain of nanomedicine. *Journal of Drug Delivery Science and Technology*, *91*, 105157. https://doi.org/10.1016/j.jddst.2023.105157

Hasanah, I. U., Tabroni, I., Brunel, B., & Alan, M. (2023). Development of Media Matching Box to stimulate symbolic thinking skills in children aged 4-5 years. *Biomedical and Techno Nanomaterials*, *1*(1), 1–13. https://doi.org/10.55849/jsca.v1i1.442

Khorsandi, D., Farahani, A., Zarepour, A., Khosravi, A., Iravani, S., & Zarrabi, A. (2025). Bridging technology and medicine: Artificial intelligence in targeted anticancer drug delivery. *RSC Advances*, *15*(34), 27795–27815. https://doi.org/10.1039/d5ra03747f

Kumar, S., Malviya, R., Sridhar, S. B., Wadhwa, T., & Shareef, J. (2026). Artificial intelligence and machine learning driven nanorobotics for targeted brain delivery: Redefining blood-brain barrier navigation. *Journal of Neuroscience Methods*, *429*, 110695. https://doi.org/10.1016/j.jneumeth.2026.110695

Mehla, S., Arya, G. C., & Arora, V. (2025). Chapter 30—Exploring the potential of artificial intelligence in drug delivery to brain. In P. A. Chawla, R. Loebenberg, K. Dua, V. Parikh, & V. Chawla (Eds.), *Novel Drug Delivery Systems in the management of CNS Disorders* (pp. 411–428). Academic Press. https://doi.org/10.1016/B978-0-443-13474-6.00023-8

Mingliang, Z., Al-Yarimi, F. A. M., Ijaz, N., & Zeeshan, A. (2026). AI-driven entropy optimization in bio-convective third-grade nanofluid flow with electroosmotic effects. *International Communications in Heat and Mass Transfer*, *172*, 110204. https://doi.org/10.1016/j.icheatmasstransfer.2025.110204

Mishra, A., Sharma, S., & Pandey, S. K. (2025). The Present State and Potential Applications of Artificial Intelligence in Cancer Diagnosis and Treatment. *Recent Patents on Anti-Cancer Drug Discovery*, *20*(3), 287–305. https://doi.org/10.2174/0115748928361472250123105507

Naik, G. G., & Jagtap, V. A. (2024). Two heads are better than one: Unravelling the potential Impact of Artificial Intelligence in nanotechnology. *Nano TransMed*, *3*, 100041. https://doi.org/10.1016/j.ntm.2024.100041

Nopiyanti, H., Tabroni, I., Barroso, U., & Intes, A. (2023). Product Development of Unique Clothing Learning Media to Stimulate Fine Motor Skills of 4-5 Years Old Children. *Biomedical and Techno Nanomaterials*, *1*(1), 48–61. https://doi.org/10.55849/jsca.v1i1.452

Nyarko, E. N. Y., & Ofori, E. K. (2026). Chapter 3—Role of big data and artificial intelligence in renal disease diagnosis and treatment. In E. K. Ofori & S. K. Amponsah (Eds.), *Understanding Renal Biochemistry* (pp. 37–56). Academic Press. https://doi.org/10.1016/B978-0-443-33090-2.00014-X

Panchpuri, M., Painuli, R., & Kumar, C. (2025). Artificial intelligence in smart drug delivery systems: A step toward personalized medicine. *RSC Pharmaceutics*, *2*(5), 882–914. https://doi.org/10.1039/d5pm00089k

Parkhe, V., Dongale, T. D., Sathish, C. I., Singh, G., Vinu, A., & Tiwari, A. P. (2026). Recent advances in artificial intelligence integrated gold nanoparticle-based biosensors for the detection of diseases and hazards. *Microchemical Journal*, 117091. https://doi.org/10.1016/j.microc.2026.117091

Pourmadadi, M., Shabestari, S. M., Abdouss, H., Rahdar, A., Fathi-Karkan, S., & Pandey, S. (2025). Artificial intelligence-driven intelligent nanocarriers for cancer theranostics: A paradigm shift with focus on brain tumors. *Seminars in Oncology*, *52*(6), 152429. https://doi.org/10.1016/j.seminoncol.2025.152429

Samant, S. S., & Kapoor, D. U. (2026). Chapter 13—Artificial intelligence and personalized medication using nanodots. In B. G. Prajapati, D. U. Kapoor, & N. Ali (Eds.), *Nanodots for Cancer Diagnosis and Treatment* (pp. 321–346). Academic Press. https://doi.org/10.1016/B978-0-443-27511-1.00001-7

Sharma, D., Singh, J., Mehta, P., Sharma, A., Thakur, A., & Chowdhury, K. R. (2026). Chapter 19—Nanorobotics and artificial intelligence for effective nanobased intervention. In D. Sharma & I. Singh (Eds.), *Nanotherapeutics Combating Microbial Infections and Antimicrobial Resistance* (pp. 413–430). Academic Press. https://doi.org/10.1016/B978-0-443-33070-4.00002-2

Shirzad, M., Salahvarzi, A., Razzaq, S., Javid-Naderi, M. J., Rahdar, A., Fathi-karkan, S., Ghadami, A., Kharaba, Z., & Romanholo Ferreira, L. F. (2025). Revolutionizing prostate cancer therapy: Artificial intelligence – Based nanocarriers for precision diagnosis and treatment. *Critical Reviews in Oncology/Hematology*, *208*, 104653. https://doi.org/10.1016/j.critrevonc.2025.104653

Srivastava, S. K., Dhaker, K. L., & Dubey, M. (2026). Advances in synthesis and characterization of bionanomaterials by using artificial intelligence and machine learning techniques: A critical review. *Next Research*, *4*, 101257. https://doi.org/10.1016/j.nexres.2025.101257

Su, K., Qiu, J., Xu, T., & Liu, S. (2025). Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery. *Acta Pharmaceutica Sinica B*. https://doi.org/10.1016/j.apsb.2025.11.029

Taha, B. A., Addie, A. J., Kolie, L. F. Z., Wahhab, S. T., Abdulateef, S. A., Haider, A. J., Ibnaouf, K., & Arsad, N. (2026). Advancements in nanophotonics and smart nanomaterials integrated with artificial intelligence-driven gene editing: A paradigm shift in cancer diagnosis and therapeutic. *Chinese Chemical Letters*, *37*(4), 111955. https://doi.org/10.1016/j.cclet.2025.111955

Taha, B. A., Ahmed, N. M., Talreja, R. K., Haider, A. J., Al Mashhadany, Y., Al-Jubouri, Q., Huddin, A. B., Mokhtar, M. H. H., Rustagi, S., Kaushik, A., Chaudhary, V., & Arsad, N. (2024). Synergizing Nanomaterials and Artificial Intelligence in Advanced Optical Biosensors for Precision Antimicrobial Resistance Diagnosis. *ACS Synthetic Biology*, *13*(6), 1600–1620. https://doi.org/10.1021/acssynbio.4c00070

Teresia, V., Jie, L., & Jixiong, C. (202 C.E.). Interactive Learning Media Application For The Introduction Of Human Needs In Children Aged. *Biomedical and Techno Nanomaterials*, *1*(1), 25–36. https://doi.org/10.55849/jsca.v1i1.406

Varshney, M., Gehlot, A., & Sharma, A. (2025). The synergy of artificial intelligence in biomaterials, regenerative medicine and drug delivery. *Next Bioengineering*, *1*, 100001. https://doi.org/10.1016/j.nxbio.2025.100001

Yapa, P., Rajapaksha, S., & Munaweera, I. (2025). The integration of nanotechnology, nanomedicine, and artificial intelligence for advancements in healthcare: A conceptual review based on PRISMA method and future research directions. *Next Research*, *2*(2), 100330. https://doi.org/10.1016/j.nexres.2025.100330

Zhang, Y., Lu, Y., Li, S., Zheng, F., Dong, Y., Tang, H., Wang, X., & Wang, J. (2025). Precision theranostics in cervical Cancer: Harnessing stimuli-responsive hydrogels for tumor microenvironment-targeted therapy and diagnosis. *Materials Today Bio*, *35*, 102392. https://doi.org/10.1016/j.mtbio.2025.102392